Drug Related Products
(AUXL) Auxilium Pharma Awaiting FDA Decision
Auxilium Pharma (AUXL) is currently awaiting a decision from the U.S. Food and Drug Administration (FDA) on its key pipeline candidate, Xiaflex, which is under FDA review for the treatment of Dupuytren’s Contracture. In September, Auxilium received a major...
(PRGO) Perrigo Company – PEG Ratio of Just 0.94 – Growth Expected to Continue in Fiscal 2010
Perrigo Company (PRGO) has surprised on estimates the last two quarters as it reported record sales for fiscal 2009. PRGO has a PEG ratio of just 0.94.
Company Description
Perrigo manufactures over-the-counter and prescription...
(SLXP) Salix Pharmaceuticals Gets Marketing Approval
Salix Pharmaceuticals, Ltd. (SLXP) received positive news yesterday when the U.S. Food and Drug Administration (FDA) granted marketing approval for Metozolv ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. Metozolv ODT received approval...
(SLXP) Salix Pharmaceuticals’ Drug Gets Priority Status
Salix Pharmaceuticals Ltd. (SLXP) yesterday announced that the U.S. Food and Drug Administration (FDA) has granted priority review status to its new drug application (NDA) for rifaximin 550 mg. Salix is seeking approval for the use of rifaximin for the...
(AUXL) Trading FDA Decisions with Calendar Spreads
Joe Kunkle, The Investment U Research Team
FDA approvals/rejections...
(PRGO) Perrigo Company – ROE of 17% – more than the double the industry average of 8%
Perrigo Co. (PRGO) has a return on equity (ROE) of 17%, more than the double the industry’s average of 8%. The company’s earnings per share are expected to grow by 21% over the next 3 – 5 years, while the industry average expectation stands at 15%.
Company Description
Perrigo...
(PBH) Prestige Brands – Prestige Brands distributes over-the-counter healthcare, personal care and household products
Prestige Brands Holdings, Inc. (PBH) is weathering the economic storm with its strong brands such as Comet and Little Remedies. Net income for the second quarter grew 25% from a year ago. PBH is trading at 9.8x forward earnings.
Company Description
Prestige Brands...
(PRGO) – Perrigo Company – largest manufacturer of store brand over-the-counter pharmaceutical products
Perrigo Company (PRGO) has acquired 2 more laboratories this quarter in a focused effort on growth in existing markets. The company is also coming off of a record quarterly earnings report.
Company Description
Perrigo is the nations largest manufacturer...
(PRGO) – Perrigo Company – largest manufacturer of store brand over-the-counter pharmaceutical products
Perrigo Company (PRGO) has acquired 2 more laboratories this quarter in a focused effort on growth in existing markets. The company is also coming off of a record quarterly earnings report.
Company Description
Perrigo is the nations largest manufacturer...
(PRGO) – Perrigo Company – largest manufacturer of store brand over-the-counter pharmaceutical products
Perrigo Company (PRGO) has acquired 2 more laboratories this quarter in a focused effort on growth in existing markets. The company is also coming off of a record quarterly earnings report.
Company Description
Perrigo is the nations largest manufacturer...
(PRGO) – Perrigo Company – largest manufacturer of store brand over-the-counter pharmaceutical products
Perrigo Company (PRGO) has acquired 2 more laboratories this quarter in a focused effort on growth in existing markets. The company is also coming off of a record quarterly earnings report.
Company Description
Perrigo is the nations largest manufacturer...
(PRGO) – Perrigo – profit increased by 46% from demand for its consumer health care products
Perrigo Co. (PRGO) has been performing well in a down market, and analysts have been boosting forecasts. Fiscal full-year earnings estimates are up 2% in just the past week. The company announced record fiscal fourth-quarter results in mid-August.
Company...
(PRGO) – Perrigo – profit increased by 46% from demand for its consumer health care products
Perrigo Co. (PRGO) has been performing well in a down market, and analysts have been boosting forecasts. Fiscal full-year earnings estimates are up 2% in just the past week. The company announced record fiscal fourth-quarter results in mid-August.
Company...
(PRGO) – Perrigo – profit increased by 46% from demand for its consumer health care products
Perrigo Co. (PRGO) has been performing well in a down market, and analysts have been boosting forecasts. Fiscal full-year earnings estimates are up 2% in just the past week. The company announced record fiscal fourth-quarter results in mid-August.
Company...
(PRGO) – Perrigo – profit increased by 46% from demand for its consumer health care products
Perrigo Co. (PRGO) has been performing well in a down market, and analysts have been boosting forecasts. Fiscal full-year earnings estimates are up 2% in just the past week. The company announced record fiscal fourth-quarter results in mid-August.
Company...
(PRGO) – Perrigo – profit increased by 46% from demand for its consumer health care products
Perrigo Co. (PRGO) has been performing well in a down market, and analysts have been boosting forecasts. Fiscal full-year earnings estimates are up 2% in just the past week. The company announced record fiscal fourth-quarter results in mid-August.
Company...
(PRGO) – Perrigo – return on equity (ROE) of 18%, which more than doubles the industry average of 7%
Perrigo Co. (PRGO) is seeing higher forecasts from analysts. The company offers a return on equity (ROE) of 18%, which more than doubles the industry average of 7%. Earnings per share are expected to grow by 20% over the next 3 – 5 years, outpacing the industry average of...
(PRGO) – Perrigo – return on equity (ROE) of 18%, which more than doubles the industry average of 7%
Perrigo Co. (PRGO) is seeing higher forecasts from analysts. The company offers a return on equity (ROE) of 18%, which more than doubles the industry average of 7%. Earnings per share are expected to grow by 20% over the next 3 – 5 years, outpacing the industry average of...
(PRGO) – Perrigo – return on equity (ROE) of 18%, which more than doubles the industry average of 7%
Perrigo Co. (PRGO) is seeing higher forecasts from analysts. The company offers a return on equity (ROE) of 18%, which more than doubles the industry average of 7%. Earnings per share are expected to grow by 20% over the next 3 – 5 years, outpacing the industry average of...
(PRGO) – Perrigo – return on equity (ROE) of 18%, which more than doubles the industry average of 7%
Perrigo Co. (PRGO) is seeing higher forecasts from analysts. The company offers a return on equity (ROE) of 18%, which more than doubles the industry average of 7%. Earnings per share are expected to grow by 20% over the next 3 – 5 years, outpacing the industry average of...